These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34431557)

  • 21. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
    Lazarus HM; Zhang MJ; Carreras J; Hayes-Lattin BM; Ataergin AS; Bitran JD; Bolwell BJ; Freytes CO; Gale RP; Goldstein SC; Hale GA; Inwards DJ; Klumpp TR; Marks DI; Maziarz RT; McCarthy PL; Pavlovsky S; Rizzo JD; Shea TC; Schouten HC; Slavin S; Winter JN; van Besien K; Vose JM; Hari PN
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):35-45. PubMed ID: 20053330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
    Rezvani AR; Storer B; Maris M; Sorror ML; Agura E; Maziarz RT; Wade JC; Chauncey T; Forman SJ; Lange T; Shizuru J; Langston A; Pulsipher MA; Sandmaier BM; Storb R; Maloney DG
    J Clin Oncol; 2008 Jan; 26(2):211-7. PubMed ID: 18056679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
    Pollack SM; Steinberg SM; Odom J; Dean RM; Fowler DH; Bishop MR
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):223-30. PubMed ID: 19167682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
    van Besien K; Loberiza FR; Bajorunaite R; Armitage JO; Bashey A; Burns LJ; Freytes CO; Gibson J; Horowitz MM; Inwards DJ; Marks DI; Martino R; Maziarz RT; Molina A; Pavlovsky S; Pecora AL; Schouten HC; Shea TC; Lazarus HM; Rizzo JD; Vose JM
    Blood; 2003 Nov; 102(10):3521-9. PubMed ID: 12893748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
    Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
    J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
    Cao TM; Horning S; Negrin RS; Hu WW; Johnston LJ; Taylor TL; Shizuru JA; Hoppe RT; Brown BW; Blume KG; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2001; 7(5):294-301. PubMed ID: 11400952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Kawashima I; Inamoto Y; Maeshima AM; Nomoto J; Tajima K; Honda T; Shichijo T; Kawajiri A; Takemura T; Onishi A; Ito A; Tanaka T; Fuji S; Kurosawa S; Kim SW; Maruyama D; Tobinai K; Kobayashi Y; Fukuda T
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):294-300. PubMed ID: 29037890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
    Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
    Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
    JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
    Abou-Nassar KE; Stevenson KE; Antin JH; McDermott K; Ho VT; Cutler CS; LaCasce AS; Jacobsen ED; Fisher DC; Soiffer RJ; Alyea EP; Koreth J; Freedman AS
    Bone Marrow Transplant; 2011 Dec; 46(12):1503-9. PubMed ID: 21258420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
    Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
    Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
    J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.